Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403

被引：5

作者：

Goldberg, S. ^{[1
]}

Redman, M. ^{[2
]}

Lilenbaum, R. ^{[1
]}

Politi, K. ^{[1
]}

Stinchcombe, T. ^{[3
]}

Horn, L. ^{[4
]}

Chen, E. ^{[5
]}

Mashru, S. ^{[6
]}

Gettinger, S. ^{[1
]}

Melnick, M. A. ^{[7
]}

Miao, J. ^{[2
]}

Moon, J. ^{[2
]}

Kelly, K. ^{[8
]}

Gandaram, D. ^{[9
]}

机构：

[1] Yale Univ, Sch Med, New Haven, CT USA

[2] Fred Hutchinson Canc Res Ctr, Swog Stat Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[3] Duke Univ, Durham, NC USA

[4] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[5] Kaiser Permanente, Bellflower, CA USA

[6] Kaiser Permanente, Portland, OR USA

[7] Yale Sch Med, New Haven, CT USA

[8] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA

[9] Univ Calif Davis, Ctr Comprehens Canc, Div Hem Oncol, Sacramento, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

NSCLC; EGFR;

D O I：

10.1016/j.jtho.2018.08.290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA10.04

引用

页码：S343 / S344

页数：2

共 50 条

[31] CARDIOVASCULAR EVENTS IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER ON OSIMERTINIB
Peleg, Ariel
Ibtida, Ishmam
Liu, Jennifer
Steingart, Richard
Yu, Anthony
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3288 - 3288
[32] Neurological death in patients with EGFR-mutant non-small cell lung cancer.
Ramotar, Matthew
Barnes, Sierra
Doherty, Mark
Shultz, David Benjamin
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] EGFR-mutant non-small cell lung cancer in Aberdeen, Scotland - Treatment and outcomes
El-Shakankery, K.
Steven, E.
Clark, C.
Stilwell, C.
Kerr, K.
Nicolson, M.
[J]. LUNG CANCER, 2017, 103 : S35 - S36
[34] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Ana Ortega-Franco
Shereen Rafee
[J]. Oncology and Therapy, 2022, 10 : 13 - 22
[35] Radiomic Signature to Predict Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer
Minatta, J. N.
Deza, D.
Aineseder, M.
Nunez, M. Mestas
Mosquera, C.
Lupinacci, L.
Benitez, S.
Seehaus, A.
Luna, D.
Beresnak, A.
Diaz, F.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1166 - S1166
[36] Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
Chmielecki, Juliann
Foo, Jasmine
Oxnard, Geoffrey R.
Hutchinson, Katherine
Ohashi, Kadoaki
Somwar, Romel
Wang, Lu
Amato, Katherine R.
Arcila, Maria
Sos, Martin L.
Socci, Nicholas D.
Viale, Agnes
de Stanchina, Elisa
Ginsberg, Michelle S.
Thomas, Roman K.
Kris, Mark G.
Inoue, Akira
Ladanyi, Marc
Miller, Vincent A.
Michor, Franziska
Pao, William
[J]. SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)
[37] Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
Xiong, Liwen
Lou, Yuqing
Bai, Hao
Li, Rong
Xia, Jinjing
Fang, Wentao
Zhang, Jie
Han-Zhang, Han
Lizaso, Analyn
Li, Bing
Gu, Aiqin
Han, Baohui
[J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019,
[38] Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
Zhang, Hongye
Wang, Ruiyu
Wang, Mingxia
Luo, Judong
Liu, Changmin
[J]. TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 754 - 762
[39] A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Yoon, S. H.
Kim, Y. S.
Chung, J. H.
Seol, H. Y.
Kim, M. H.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[40] Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
Ahn, M. -J.
Yang, J.
Yu, H.
Saka, H.
Ramalingam, S.
Goto, K.
Kim, S. -W.
Yang, L.
Walding, A.
Oxnard, G. R.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S115 - S115

← 1 2 3 4 5 →